<DOC>
	<DOCNO>NCT00960180</DOCNO>
	<brief_summary>This first-in-human study MR1817 . This study provide initial assessment safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) MR1817 administration ascend single oral dos healthy adult subject .</brief_summary>
	<brief_title>Study Evaluating Single Ascending Doses MR1817</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 Men woman nonchildbearing potential ( WONCBP ) age 18 55 year inclusive screening . 2 Body mass index ( BMI ) range 18 32 kg/m2 body weight â‰¥50 kg . 3 Healthy determine investigator basis screen evaluation . Exclusion criterion : 1 Presence history disorder may prevent successful completion study . 2 Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . 3 History drug abuse within 1 year study day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>